Clinical Trial Update: Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy, safety, and tolerability of JNJ-42847922 for insomnia disorder without psychiatric comorbidity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• JNJ-42847922

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Insomnia | Phase 2 | Status: COMPLETED